Remnant Cholesterol Could Flag Kidney Patients' Heart Risk

Adults with chronic kidney disease or on hemodialysis may someday have a lipid-based tool to help gauge cardiovascular risk.

Updated on Nov. 3, 2026 in Heart Disease

Photograph of a rack of plain glass test tubes holding pale amber fluid on a stainless lab bench, with a blurred centrifuge behind, suggesting routine blood testing.
Two early studies presented at ASN Kidney Week 2026 in Denver suggest remnant cholesterol from a routine lipid panel may help flag heart risk in kidney patients. AI Illustration. Upload story photo >

Two posters presented at ASN Kidney Week 2026 in Denver suggest that remnant cholesterol, a lipid measure calculated from a standard lipid panel, may help stratify kidney disease severity and cardiovascular death risk in people with chronic kidney disease and those on hemodialysis. The findings are early, observational, and drawn from single-center or retrospective samples.

Why it matters

Cardiovascular disease is a leading cause of death for people with kidney disease, and standard risk tools often underperform in this group. If remnant cholesterol proves useful in larger studies, it could offer a low-cost way to refine risk assessment using labs many patients already receive.

The hemodialysis analysis followed 346 patients for a median of about 7.1 years and found high remnant cholesterol independently associated with cardiovascular death but not all-cause death. The CKD analysis was retrospective and compared remnant cholesterol indices against C-reactive protein, a standard inflammation marker.

The players

ASN Kidney Week 2026

The annual meeting of the American Society of Nephrology, the leading professional society for kidney specialists and researchers, where these posters were presented.

Peking University Third Hospital

A major hospital in Beijing, China, whose researchers conducted the hemodialysis study examining remnant cholesterol and cardiovascular mortality.

The details

Remnant cholesterol is the cholesterol carried by triglyceride-rich particles left over after LDL and HDL are accounted for, and it is estimated by subtracting LDL and HDL cholesterol from total cholesterol. In the hemodialysis study, patients were split at a median value of 0.72 mmol/L, and the high group had far more cardiovascular deaths over follow-up. Researchers also tested remnant cholesterol-based indices, including RCII and CTI, which appeared to track CKD risk somewhat better than CRP in the CKD cohort.

Timeline

  1. Hemodialysis enrollment ran from 2010 to 2025, and CKD patients were treated from 2011 to 2020.

  2. Findings were presented at ASN Kidney Week 2026 in Denver on October 24, 2026.

Health Landscape

Cardiovascular disease remains a leading cause of death in chronic kidney disease, and risk tools built for the general population often miss the mark for dialysis patients. Researchers are testing whether lipid and inflammation-based markers can close that gap, though most evidence so far comes from observational studies.

If you have chronic kidney disease or are on dialysis, these findings are worth raising with your nephrologist or primary care doctor, especially if you already track a standard lipid panel. Because the research is preliminary, no changes to testing or treatment should be made based on it alone.

The takeaway

Remnant cholesterol may eventually help flag cardiovascular risk in kidney patients, but these results are early and observational. Ask your care team whether your lipid panel results are being used alongside kidney and heart risk assessments.

Further reading

For broader context on how cholesterol measures relate to heart risk, explore our Heart Disease coverage.

Source note: This article includes information reported by Pharmacytimes.